These authors contributed equally to this work Aim: Parkinson's disease and schizophrenia are clinical end points of dopaminergic deficit and excess, respectively, in the mid-brain. In accordance, current pharmacological interventions aim to restore normal dopamine levels, the overshooting of which culminates in adverse effects which results in psychotic symptoms in Parkinson's disease and extra-pyramidal symptoms in schizophrenia. Currently, there are no laboratory assays to assist treatment decisions or help foresee these drug side-effect outcomes. Therefore, the aim was to discover a protein biomarker that had a varying linear expression across the clinical dopaminergic spectrum. Materials and methods: iTRAQ-based proteomic experiments along with mass spectrometric analysis was used for comparative proteomics using cerebrospinal fluid (CSF). CSF fluid was collected from 36 patients with Parkinson's disease, 15 patients with urological diseases that served as neurological controls, and seven schizophrenic patients with hallucinations. Validation included ELISA and pathway analysis to highlight the varying expression and provide plausible molecular pathways for differentially expressed proteins in the three clinical phenotypes. Results: Protein profiles were delineated in CSF from Parkinson's disease patients, neurological control and schizophrenia, respectively. Ten of the proteins that were identified had a linear relationship across the dopaminergic spectrum. α-2-Macroglobulin showed to be having high statistical significance on inter-group comparison on validation studies using ELISA. Conclusions: Non-gel-based proteomic experiments are an ideal platform to discover potential biomarkers that can be used to monitor pharmaco-therapeutic efficacy in dopamine-dictated clinical scenarios. α-2 Macroglobulin is a potential biomarker to monitor pharmacological therapy in Parkinson's disease and schizophrenia.
Introduction
Parkinson's disease and schizophrenia are two neurological diseases that are very clinically diverse but are etiopathologically related to neurotransmitter dopamine. While the motor symptoms of Parkinson's disease result from deficient dopaminegenerating neurons, the psychotic symptoms of schizophrenia are related to an excess of dopaminergic activity. 1 In accordance, the pharmacological interventions by clinicians, and their respective responses in Parkinson's disease and schizophrenia, pertains to concentrations of dopamine in the mid-brain. 2 Treatment in Parkinson's disease is therefore given to enhance dopamine in the neurons of the brain, while medications in schizophrenia include drugs that reduce the synthesis and activity of dopamine as a signal between neurons in the mid-brain. Therefore, during the course of Parkinson's therapy, dopamine levels tend to increase physiological levels, leading to symptoms of schizophrenia. 3 Likewise, neuroleptic drugs that are used in the treatment of schizophrenia lower the amounts of dopamine and produce extra-pyramidal side effects. 4 Although these side effects are slightly reduced with second-generation anti-psychotic drugs, problems that pertain to the side effects of medications continue to be reported. 5 For diseases such as Parkinson's and schizophrenia, a major hurdle is that there are currently no investigations that can guide treatment decisions or help predict adverse side effects of the drugs used. As a reason, there is a high probability of overshooting the point of normal dopaminergic state, resulting in patients succumbing to the side effects, which is a clinical state at the other end of the dopaminergic spectrum. 6 The detailed neuro-anatomy, molecular pathology and side effects of current pharmacological interventions in Parkinson's disease and schizophrenia have been comprehensively explained and reviewed by our group. 7 Clinicians have to depend on patient compliance and symptoms to comprehend the efficacy of drugs that are administered. 8 This causes a lot of inconvenience to patients and neurologists. This drawback also has an indirect social and economical constraint in society.
Clinical proteomics offers a platform to discover biomarkers to understand pathological states and treatment response. [9] [10] [11] Potential biomarkers have been discovered in cerebrospinal fluid (CSF) using gel-based proteomic experiments for neurological diseases such as tubercular meningitis and Alzheimer's disease. 12, 13 In our previous studies, we have highlighted the prospects of identifying protein biomarkers in serum and CSF to monitor the pharmaco-therapy of Parkinson's disease and schizophrenia. [14] [15] [16] In this study, we seek to identify potential biomarkers that are differentially expressed in the CSF across the dopaminergic-deficient state of Parkinson's disease, the normal dopaminergic state, and the dopaminergic excess state of schizophrenia using isobaric Tag for Relative and Absolute Quantitation (iTRAQ). iTRAQ proteomic experiments have the following advantages: (1) they provide qualitative as well as quantitative analysis; (2) it is an amino acid independent tag labelling technology; (3) up to eight clinical phenotypes can be analyzed in a single experiment; and (4) low abundant protein quantification is possible. This should pave the way to monitor pharmacology-based therapeutic efficacy in the dopamine-mediated disorders of Parkinson's disease and schizophrenia.
Methods

Ethics, Consent, Sample Collection
This study was approved by the ethics committee at All India Institute of Medical Sciences, New Delhi (IEC/NP-535/4.11.2013) and protocols followed were in accordance with the ethical standards formulated in the Helsinki Declaration. Screening of patients was done at neurology and psychiatry clinics at the institute as per the criteria provided below. Written informed consent was obtained from participants before obtaining CSF and for subsequent analysis. For neurological controls, patients with bladder, prostate and uterine pathologies were screened at urology and gynecology clinics, and recruited for surgeries for spinal anesthesia. Lumbar puncture was done by positioning the spinal needle between the two vertebral spines at the L4-L5 level. CSF (2 mL) was collected in sterile conditions, transported in microfuge tubes in an ice box and centrifuged at 4°C for 5 min at 3,000 rpm. The supernatant was aliquoted and stored at −80°C until further analysis. The tubes were placed on ice at the time of sample collection in the operating theaters. The samples were immediately centrifuged to eliminate any possible contamination by red blood cells (RBCs). They were then aliquoted to new sterile tubes, labeled and stored at −80°C. Quality control was ensured by CSF sample collection in sterile conditions during the operation. They were aliquoted and stored at −80°C and minimum freeze thawing of the samples was complied with to minimize protein degradation. Labeling, annotation and clinical date of collection was done in a disciplined manner. The peptide intensities on mass spectrometric analysis ensured consistent qualitative and quantitative information. The entire period of patient screening, recruitment and sample collection lasted nine months. (UPDRS), where a score of 0 represented no disability, 1 represented minimum disability and a score of 199 represented complete disability. 17 The Hoehn and Yahr scale was used to describe the progress of symptoms in Parkinson's patients and was graded from stage 1 to stage 5. 18 Diagnosis of schizophrenia was made as per ICD 10. 19 Naïve patients with Parkinson's disease and schizophrenia were recruited for the discovery phase of experiments. The same naïve patients along with patients who were on pharmacological therapy were recruited for the validation phase of the study. Patients with urological disorders or pregnant women requiring surgical interventions under spinal anesthesia were admitted as neurological controls. At the time of recruitment, these patients were only taking nutritional supplements. Detailed clinical examination was carried out on these patients to rule out any neurological abnormalities. At the time of administering spinal anesthesia, lumbar puncture was done and the CSF was collected from these patients and was annotated as neurological control samples. Exclusion criteria:
Patient Inclusion And Exclusion Criteria
Patients with other co-existing pathologies and those patients on non-allopathic alternative forms of therapy were excluded from the study.
Chemicals And Consumables
Dithiothreitol (DTT), iodoacetamide and formic acid were purchased from Sigma (St. Louis, MO, USA). Trypsin (modified, sequencing grade) was purchased from Promega. The isobaric tags for relative and absolute quantitation (iTRAQ) reagents were procured from ABSciex (Foster City, CA, USA). The LC-MS grade water and acetonitrile were purchased from J. T. Baker. The cation exchange chromatography column was procured from ABSciex. ELISA conducted in this study was procured from Abcam. All other chemicals used in the experiments were of analytical grade.
Protein Quantification And Internal Standard
Two CSF samples from naïve Parkinson's disease patients, two CSF samples from naïve schizophrenia and two CSF samples from neurological controls were taken for the discovery phase of the proteomic experiments by iTRAQ. Protein concentrations of CSF samples of each of these patients were determined using Bradford reagent (Sigma, USA). Equal concentrations of proteins from all these six samples were pooled as internal standard for the sake of normalization in each experiment.
Protein Digestion And Isobaric Tags For Relative And Absolute Quantitation Labeling
Protein (45 μg) from each sample was reduced with 25 mM DTT for 30 min at 60°C and alkylated with 55 mM iodoacetamide for 20 min at room temperature. Each of these protein samples were digested for 16 h with trypsin in a 1:10 ratio at 37°C. Digested peptides were labeled with iTRAQ reagents following the method provided by the manufacturer (ABSciex). The following experimental design used for the labeling of clinical phenotypes and internal standard. In brief, all vials of iTRAQ labeling tags 114, 115 and 116 were reconstituted in 70 μl of absolute ethanol. This was added to every sample and incubated for 2 h at room temperature, and the reaction was quenched using 50 μl milli-Q water. The three iTRAQ-labeled samples in each set were then pooled separately into a single vial and vacuum-dried using a vacuum concentrator (Eppendorf, USA). The dried samples were reconstituted in 8 mM ammonium formate buffer (pH 3) and were fractionated by cation exchange using an isotope-coded affinity tag-cartridge (ABSciex). Peptides were eluted with 500 μl of 35, 50, 75, 100, 125, 150, 250, 350, and 500 mM concentrations of ammonium formate buffer, pH 3, and vacuum-dried.
Reverse-Phase Separation And Mass Spectrometry Analysis
The peptide fractions were loaded onto a reverse-phase C18 analytical column associated with a trap column (ChromXP nano-LC Trap column 350 μm × 0.5 mm, 3 μm 120 Å). The peptide separation was performed using Eksigent nano-LC 425 coupled with triple Time-of-Flight (TOF)-6600 (ABSciex). The peptide fractions were premixed in loading buffer (mobile phase A: 100% water and 0.1% formic acid) and 10 μL was loaded on a trap column with a flow rate of 2 μl/min. The retained peptides were washed isocratically by loading buffer for 45 min to remove excess salt. The peptides were resolved on an analytical column with a multi-step linear gradient of loading buffer and elution buffer (mobile phase B: 100% acetonitrile and 0.1% formic acid) at a flow rate of 250 nl/min. The gradient elution was initiated using 5% elution buffer and was held for 1 min, with linear increase of 10% for 10 min, 35% for 70 min, and 50% for 80 min. The gradient was maintained at 80% B for 8 min before being re-equilibrated to 5% B for 18 min. The Q-TOF 6600 (ABSciex) was operated in information-dependent acquisition (IDA) mode. The complete MS spectra were acquired in positive ion mode in an m/z ratio of 400-1600 Da, with a 0.25 seconds TOF-MS accumulation time, whereas the MS/MS product ion scan was performed in the mass range of 100-1,800 Da with an accumulation time of 0.07 seconds. The mass spectrometric settings were as follows: ion spray voltage floating: 2,400 V, curtain gas: 25, ion source gas 1:25, interface heater temperature: 75°C, and declustering potential: 80 V. For 3 seconds, former target ions were excluded and 25 candidate ions were monitored per MS cycle. IDA advanced "rolling collision energy" was applied for subsequent MS and MS/MS scans.
Database Search And Analysis
Data in the constituted MS and MS/MS spectra scan were received from Triple TOF 6600 in the form of .wiff files.
These .wiff files from each iTRAQ experiment were submitted for protein identification to ProteinPilot™ software (v.5.0.1, ABSciex), using a Paragon search method against Homo sapiensSwissProt database. The following search parameters were used: trypsin as the digestion enzyme with two missed cleavages, iodo-acetamide modification on cysteine residue, iTRAQ 3-plex modification of the Ntermini of peptides and of the side chains of lysine, and proteins were identified with global protein false discovery rate (FDR) of 1%. From the search results obtained, the ratios with respect to internal standard were selected and the average of two sets of experiments was taken. Proteins which had a linear set of ratios across the three phenotypes of Parkinson's disease, controls and schizophrenia were chosen for further analysis. Proteins with a total number of peptides identified with 95% confidence limit and, having a linear expression along the three phenotypes was estimated. Venny 2.1.0 (Bioinfo GP, CNB-CSIC) was used to group and compare the number of proteins across the three phenotypes on the basis of UNIPROT identifications.
Pathway Analysis
All the information about genes corresponding to identified proteins and their related functions were searched from NCBI and UNIPROT. The proteins were then studied for their biological interaction network in Parkinson's disease and schizophrenia pathways using the KEGG and Schizo-Pi database. 20 The Cytoscape v2.8.0 software 21, 22 and plugin Michigan Molecular Interactions (MiMI) 23 were used to obtain and merge human gene regulatory interactome from well-known databases including STRING, MINT and HPRD. [24] [25] [26] 
Results
Clinical Profile
A total of 58 CSF samples from 36 Parkinson's disease patients, seven schizophrenia patients and 15 from either pregnant women or patients with urological disease were recruited as neurological controls for this study. Six of these samples were used for the discovery phase of the experiments by iTRAQ ( Table 1 ). Pharmacological therapy was used in the treatment of 32 of these patients, whose details are provided in Table S1 . All the 58 samples were used in the validation phase of the experiment by ELISA. The demographic parameters of patients recruited are provided in Table 2 . The median (IQR) age of 36 Parkinson's disease patients and 7 schizophrenia patients was 51.0 (42.5-58.5) and 23.0 (21.0-28.0) years, respectively. The difference in median age between these two groups was statistically significant (p= 0.013).
iTRAQ Analysis And Protein Profiling
A total of 692, 795 and 848 proteins were identified in patient CSF samples of Parkinson's disease, healthy control and schizophrenia, respectively (Table S2 ). Proteins were quantified and an internal standard was made by mixing equimolar amounts of proteins from two samples each from Parkinson's disease, neurological controls and schizophrenia. The mean ratio of protein levels across the three phenotypes was calculated using data obtained from the search results. A total of 961 proteins were identified across the three clinical phenotypes (Figure 1) . A classification for protein in each clinical phenotype was made based on the number of peptides identified ( Figure S1 ). The percentages roughly correspond to their abundance in the CSF and are dependent on sensitivity of the mass spectrometer and ionization potential of the peptides. There were 10 proteins that showed either an increase or a decrease across the three clinical phenotypes. Inter-phenotype comparisons were made and extent of correlation (m) and accuracy of linearity across the spectrum (R 2 ) was derived from the line equations and are provided in Table 3 . The identified proteomes were classified according to their role in different biological processes and molecular function ( Figure 2 ). Seven proteins showed a linear upregulation and three proteins showed downregulation across Parkinson's disease, neurological control and schizophrenia. The trend lines corresponding to the protein levels in the three phenotypes are shown in Figure 3 and corresponding mass spectrometric peaks as obtained from Protein Pilot software are shown in Figure S2 . Pathway analysis was carried out to delineate the interacting proteins and place the differential expression with respect to dopaminergic disease in the right perspective. The salient outcomes of the network analysis are provided in Figure 4 
ELISA
For the list of proteins that were differentially expressed, proteins with at least 90% of identified peptides showing a linear correlation with dopamine spectrum were considered for validation studies. ELISA was therefore conducted for α2M. The assay characterization and performance of α2M significance. The ratio of Parkinson's disease with schizophrenia and ratio of control with schizophrenia are 3.5 and 2.0, respectively. It may be noted that the ratios for the same using the iTRAQ experiment were 2.5 and 1.3, respectively. The slope of linearity across the spectrum in the ELISA and iTRAQ is 0.43 and 0.6, respectively. The results of the validation phase, therefore, reiterate the results of the discovery phase. Due to the high heterogeneity among patients with respect to severity of the disease or the quality of pharmacological intervention, intra-group comparisons yielded no significant results. However, when the concentrations were grouped based on intervention, as naïve and treated, the slope of linearity across the spectrum was in the order of 0.3 and an R 2 value was 0.8. F-statistics were found to be 402.8 (P<0.01). Age, gender and duration of the disease were seen not to be having a correlation with α2M concentrations, hence ruling out these variables as confounding factors (Table 5) The pharmaco-therapeutic monitoring value of CSF α2M in Parkinson's disease and schizophrenia can be inferred from Table 6 .
Discussion
Clinical Profile
Parkinson's disease and the schizophrenia groups have a higher male gender representation as compared to female gender. This observation is consistent with the fact that the incidence of these two dopamine-mediated clinical states to a large extent affects the male population. 27 The median age of the schizophrenia group and the Parkinson's disease group varied significantly in the study. It may be observed that the incidence of Parkinson's disease increases above the age of 60 years, with only 4% who are under the age of 50 years, 28 whereas the incidence of schizophrenia is 16-25 years. 29 
Biological Process And Molecular Function Of Identified Proteins
There are minimal variations in the number of identified proteins represented across the three clinical phenotypes of Parkinson's disease, neurological controls and schizophrenia with respect to biological processes and molecular function. This suggests that neuronal dysfunction in Parkinson's disease and schizophrenia is a result of an imbalance of multiple physiological cellular processes. It is therefore implied that quantitative differences in the expression of certain proteins regulation of some of the proteins is responsible for deviation from the physiological state to pathological states of Parkinson's disease and schizophrenia.
Differentially Expressed Proteins Melanoma Cell Adhesion Molecule
Melanoma Cell Adhesion Molecule or MCAM (CD146) is a 113-kDa cell surface adhesion glycoprotein belonging to the immunoglobulin super family and is present on T-helper cells (Th-17). 30 MCAM interacts with laminin 411, an extra-cellular matrix protein expressed on the vascular endothelial basement membrane, and facilitates T-helper cell infiltration into the brain. 31, 32 Th-17 cells induce dopaminergic neuronal glial cell death by releasing pro-inflammatory cytokines such as IL-17. 33 Interestingly, Th-17 cells play an important role in neuro-degenerative process in Parkinson's disease experimental models. 34 On the other hand, the levels of Th-17 suppressing cytokines and IL-17 are increased in schizophrenia. 35 Bioinformatics analysis, in addition to explaining the detailed chain of interactions for the above function, shows MCAM to be interacting with leucine-rich repeat kinase 2, which is involved in cellular oxidative stress in Parkinson's disease. 36 IgG Fc-Binding Protein
The role of humoral response and the involvement of immunoglobulins in neuro-degeneration that is seen in Parkinson's disease are well studied. 37 These are a class of proteins that bind to Fc region of the immunoglobulin. One such protein is FcγR that promotes neuronal degeneration that is brought about by immunoglobulin IgG that are produced against dopaminergic neurons. 38, 39 The FcγR mediates α-synuclein intracellular trafficking and pro-inflammatory signaling that is responsible for neuro-degeneration that takes place in substantia nigra pars compacta, which is a key pathological feature in Parkinson's disease. [40] [41] [42] In accordance, there is an upregulation of IgG Fc-binding protein in the CSF of Parkinson's disease as compared to healthy controls and schizophrenia patients.
Complement C3 And Complement Factor I
Complement C3 is a protein that was identified to be having an inverse correlation along the dopaminergic clinical phenotype system. The complement system is an integral part of the innate immune system that enables antibodies and phagocytic cells to clear microbes and damaged cells from an organism and promotes inflammation by classical and alternative pathways. 43 The complement system culminates in the activation of complement C3 by C3 convertase in either of the two pathways. 44 Studies have shown the implication of the complement system in the loss of dopaminergic neurons, which is a key feature of Parkinson's disease. 45 Also, proteomic studies in the Parkinson's disease patient population have indicated a marked increase of complement C3 components C3c and C3dg. 46 Similar evidence has been obtained in animal models, wherein the loss of dopaminergic neurons was induced by repeated systemic challenge with bacterial lipopolysaccharide. 47 One of the proteins that was identified was Complement Factor I that inactivates C3b (iC3b), which is one of the cleaved products of Complement C3. iC3b facilitates binding of melanized neurons by activated microglia that are increased in Parkinson's disease. 48 This confirms the involvement of the complement system in neurodegeneration.
Immunoglobulin Lambda Light Chain
The light chain component of immunoglobulins comprises of lambda chain and kappa chain. The lambda component is encoded by immunoglobulin lambda locus on chromosome 22. 49 This protein interacts with ubiquilin-1, which has an important role in unfolded protein response. 50, 51 Ubiquilin-1 has been shown to localize in Lewy bodies in Parkinson's disease. 52 It interacts with amyloid precursor protein by acting as a molecular chaperone and its reduced activity leads to increased production of pathogenic amyloid precursor protein fragments and neuronal death. 53 In summary, Parkinson's disease occurs as a result of increased amyloid precursor protein expression leading to cerebral dopamine deficits. 54 On the contrary, schizophrenia has a decreased activity of ubiquitin proteasome pathway that is implicated in its disease pathology. [55] [56] [57] Alpha-2-Macroglobulin Alpha-2-macroglobulin (α2M) is a member of the alphamacroglobulin family having protein transport function and anti-protease activity. 58 However, in the nervous system, there exists a potential relationship between α2M and degenerative dopaminergic condition of Parkinson's disease that is intricately associated with decreased striatal dopaminergic concentrations. 59, 60 This has been conclusively studied in animal models in which α2M infusion in brain decreased the concentration of dopamine. [60] [61] [62] [63] In a normal cell, dopamine transporter (DAT) mediates the uptake of dopamine from the synaptic cleft to the pre-synaptic cell. 64 The internalized dopamine is either stored in vesicles by vesicular monoamine transporter 2 (VMAT 2) or it is metabolized by the enzyme monoamine oxidase (MAO). 65 In Parkinson's disease, the expression of VMAT 2 is decreased, therefore causing accumulation of free dopamine in the cytoplasm. 66, 67 Free dopamine is rapidly oxidized to cytotoxic metabolites and reactive oxygen species (ROS), causing oxidative stress. 68 α2M and its receptor LRP (low-density lipoprotein receptor-related protein) are involved in signaling pathways activated in response to damage occurring at synaptic terminals due to inflammation or oxidative stress. 69, 70 Therefore, there is an increase in the level of α2M in Parkinson's disease, whereas, in the case of schizophrenia, there is less free dopamine in the cytoplasm because the majority of it is secreted from the pre-synaptic terminal. 71 Therefore, there is less formation of cytotoxic oxidative metabolites of dopamine in the cytoplasm resulting in decreased oxidative stress. This explains the downregulation of α2M as observed in our experiments. CSF-α2M does not correlate with the UPDRS score. This is because CSF-α2M is the averaged reflection of events in the whole brain, while UPDRS reflects progression of Parkinson's disease in the nigro-striatal pathway. 72 The identification of α2M in the discovery phase of experiments, its validation by ELISA and pathway analysis, and the high sensitivity and specificity values for α2M make it an ideal biomarker to monitor therapeutic efficacy in dopamine-mediated disease states.
In the recent past, there have been many studies that have identified CSF proteins as biomarkers in neurological diseases. These, along with our own findings, are highlighted in Table 7 .
Limitations Of The Study
1. As our institute is a tertiary health care center, recruiting naïve patients was a limiting factor. 2. Experiments have been carried out on 58 CSF samples. Validation studies on a larger cohort would be more informative for a translational product. 3. Of the 10 proteins identified in the discovery phase, only α2M has been validated with reasonable linearity and statistical significance. A higher sample number would probably help to validate the expression of these proteins
Conclusion
Non-gel-based proteomic experiments are an ideal platform for the identification of proteins in CSF that are differentially expressed across varying dopaminergic clinical phenotypes of Parkinson's disease, healthy controls and schizophrenia. The variations in expression are due to biological and functional changes that are inherent to the neurological disease and physiological condition. iTRAQ quantitation, ELISA and pathway analysis establish alpha-2-macroglobulin as a potential biomarker to monitor pharmacological efficacy in dopamine mediated states of Parkinson's disease and schizophrenia. This is the first ever study of its kind to identify proteins as potential biomarkers of pharmacological efficacy in patients with Parkinson's disease and schizophrenia.
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